Repository logo
 

Invitro antibacterial activity of imidazole and triazole-based antimicrobials against Carbapenem Resistant Enterobacteriaceae

dc.contributor.advisorNdlovu, Thandie Sylph
dc.contributor.authorRadebe, Siyabonga Protusen_US
dc.date.accessioned2022-02-22T05:16:52Z
dc.date.available2022-02-22T05:16:52Z
dc.date.issued2019-09-05
dc.descriptionThesis submitted in fulfilment of the requirements for the degree of Masters of Technology: Biomedical Technology, Durban University of Technology, Durban, South Africa, 2017.en_US
dc.description.abstractIntroduction The frequency of serious bacterial infections has increased due to the high prevalence of HIV infection, contributing to the increasing rates of multi-drug organisms which include carbapenem-resistant Enterobacteriaceae (CRE). This trend has become a serious challenge to the health care system of South Africa, resulting in the higher use of immunosuppressive and cytotoxic drugs to treat serious bacterial infections. Optimal treatment for infections caused by CRE is yet unknown. The benefits of imidazole and triazole antimicrobials have become very topical due their diverse spectrum of pharmacological properties, but its efficacy against bacterial infections has not been tested in the South African context. Aim The primary aim of this study was to determine the antibacterial effects of selected imidazole and triazole-based antimicrobials against Carbapenem-Resistant Enterobacteriaceae. Methodology Different concentrations of test drugs (ketoconazole, metronidazole and fluconazole) were used to prepare sensitivity disks and four pathogenic strains of Carbapenem Resistant Enterobacteriaceae (K. pneumonia, E. coli, S. marcescens and C. freundii) obtained from Lancet Laboratory in Durban were used to determine the antibacterial activity of the selected test drugs, using Disk Diffusion, Modified Agar Diffusion and Minimum Inhibition Concentration (MIC) method, described by Bauer et al. 1966. Results Antimicrobial Susceptibility Testing revealed that, test drugs selected for this study have no inhibition activity against CRE test organisms and biochemical tests also showed that imidazole and triazoles antimicrobials have no adverse effects on the CRE organisms. Conclusion Although the results obtained in this study indicated no activity of against CRE, laboratory studies are still necessary in modification of the imidazole and triazoles to synthesize derived drugs to confirm and optimize the antibacterial potency of these compounds.en_US
dc.description.levelMen_US
dc.format.extent73 pen_US
dc.identifier.doihttps://doi.org/10.51415/10321/3884
dc.identifier.urihttps://hdl.handle.net/10321/3884
dc.language.isoenen_US
dc.subjectKetoconazoleen_US
dc.subjectFluconazoleen_US
dc.subjectMetronidazoleen_US
dc.subjectCarbapenem-resistanten_US
dc.subjectEnterobacteriaceaeen_US
dc.subject.lcshAntibacterial agentsen_US
dc.subject.lcshEnterobacteriaceaeen_US
dc.subject.lcshAnti-infective agentsen_US
dc.subject.lcshImidazolesen_US
dc.titleInvitro antibacterial activity of imidazole and triazole-based antimicrobials against Carbapenem Resistant Enterobacteriaceaeen_US
dc.typeThesisen_US
local.sdgSDG03

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
RADEBE_Masters_Biomedical_2017.pdf
Size:
1.75 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.22 KB
Format:
Item-specific license agreed upon to submission
Description: